Incremental Prescription and Drug Costs during the Years Preceding Diabetes Diagnosis in Primary Care Practices in Germany

Abstract

Introduction: To evaluate incremental drug prescription costs before diabetes diagnosis in primary care patients in Germany. Material and Methods: Based on 400 primary care practices throughout Germany (Disease Analyzer, IMS Health, Frankfurt, Germany), we selected only patients receiving continuous treatment (age ≥ 40 years) and ascertained drug prescriptions and costs up to 6 years before diabetes was diagnosed. For control, we selected age- and sex-matched nondiabetics (n = 6 294 pairs, age 65.5 ± 10.5 years, 44 % male). We evaluated incremental prescriptions and costs by calculating differences and ratios between patients with and without a diabetes diagnosis. We also evaluated predictors of cost differences using multivariate regression models. The data used for the evaluation was taken from the period 1993 to 2002. Results: The mean number of prescriptions in the year preceding diagnosis in men and women increased 15 % and 19 %, respectively (p < 0.001). Prescription costs were 21 % (men) and 28 % (women) higher in subjects who were destined to receive a diabetes diagnosis (269 and 264 Euros per person) compared to controls (p < 0.001). Incremental prescriptions and costs were already present six years preceding diagnosis. Cardiovascular drugs had the largest impact, accounting for about two-thirds of incremental prescriptions and costs. Women had higher numbers of prescriptions and costs, however, differences and ratios were comparable to men. Incremental costs were higher in patients with private compared to statutory health insurance, and in Western compared to Eastern Germany. Discussion: Numbers of prescriptions and costs in primary care patients with future diabetes diagnosis in Germany were already increased six years before clinical detection, reflecting increased cardiovascular risk even before clinical diabetes diagnosis.

Key words

Type 2 diabetes - primary care - prescription - drug costs

References

• 1 American Diabetes Association (ADA) . Economic consequences of diabetes mellitus in the U.S. in 1997.  Diabetes Care. 1998;  21 296-309
• 2 Barber J A, Thompson S G. Analysis and interpretation of cost data in randomized controlled trials: review of published studies.  BMJ. 1998;  317 1195-2000
• 3 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs J B, Bonadonna R C, Muggeo M. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck Study.  Diabetes. 2004;  53 1782-1789
• 4 Brown J B, Nichols G A, Glauber H S, Bakst A W. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis.  Diabetes Care. 1999;  22 1116-1124
• 5 D'Agostino R B, Hamman R F, Karter A J, Mykkanen L, Wagenknech L E, Haffner S M. Insulin Resistance Atherosclerosis Study. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.  Diabetes Care. 2004;  27 2234-2240
• 6 DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group . Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Re-analysis of European epidemiological data.  BMJ. 1998;  317 371-375
• 7 Dietlein G, Schröder-Bernhardi D. Use of the mediplus patient database in health care research.  Int J Clin Pharmacol Therap. 2002;  40 130-133
• 8 Dukes M NG (ed). Drug Utilization Studies: Methods and Uses. European Series No 45. Copenhagen, Denmark; WHO Regional Office for Europe 1993: 1-4
• 12 Federal Statistic Office (eds) .Health Report for Germany. Stuttgart; Metzler-Poeschel 1998: 379-410
• 9 Grundy S M, Brewer B, Cleeman J I, Smith S C, Lenfant C for the conference participants. Definition of the metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition.  Circulation. 2004;  109 433-438
• 10 Gulliford M C, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes.  Diabetes Care. 2005;  28 47-52
• 11 Haffner S M, Stern M P, Hazuda H P, Mitchell B D, Patterson J K. Cardiovascular risk factors in confirmed prediabetic individuals.  JAMA. 1990;  263 2893-2898
• 14 Hu F B, Stampfer M J, Haffner S M, Solomon C G, Willett W C, Manson J E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.  Diabetes Care. 2002;  25 1129-1134
• 15 Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K DECODE Study Group for the. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.  Arch Int Med. 2004;  164 1066-1076
• 16 McPhillips J B, Barrett-Connor E, Wingard D L. Cardiovascular disease risk factors prior to diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults.  Am J Epidemiol. 1990;  131 443-453
• 17 Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 diabetes mellitus in elderly subjects.  Diabetologia. 1993;  36 553-559
• 18 Nichols G A, Glauber H S, Brown J B. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis.  Diabetes Care. 2000;  23 1654-1659
• 19 OECD Health Data 2002. A software for the comparative analysis of 29 health systems. OECD electronic editions catalogue. 2002
• 20 Rathmann W, Haastert B, Roseman J M, Gries F A, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany.  Diabetes Care. 1998;  21 389-397
• 24 Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R. et al . High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000.  Diabetologia. 2003;  46 182-189
• 21 Reilly M P, Rader D J. The metabolic syndrome: more than the sum of its parts?.  Circulation. 2003;  108 1546-1551
• 22 Selby J V, Ray G T, Zhang D, Colby C J. Excess costs of medical care for patients with diabetes in a managed care population.  Diabetes Care. 1997;  20 1396-1402
• 23 The European Group for Study of Insulin Resistance . Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome.  Diabetes Metab. 2002;  28 364-376